PACTR202402866059449
Not yet recruiting
Phase 4
Efficacy and Safety of empagliflozin in patients with hepatic ascites: a randomized controlled trial
ConditionsDigestive System
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Digestive System
- Sponsor
- one
- Enrollment
- 60
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. 18 years old or older.
- •2\. Decompensated liver cirrhosis complicated with ascites.
- •3\.Ability to understand and willingness to participate and sign a written informed consent document
Exclusion Criteria
- •1\.age under 18 years old;
- •2\.History of any attack of hypoglycemia (defined as serum glucose less than 70 mg/dl) either symptomatic or a symptomatic.
- •3\.vitally unstable pt
- •4\.Patients who receive non\-selective B\-blockers.
- •5\.History of recurrent urinary tract infection defined as more than 2 infections in last 6 months
- •6\.Pregnancy and breast feeding
- •7\.History of hypersensitivity to any SGLT2 inhibitor
- •8\.Presence of hepatocellular carcinoma or any other malignancy.
- •9\.eGFR below 45mL/min/1\.73m2 or decrease in eGFR by \>30% between screening
- •10\. Patients with history of diabetes mellitus complicated with diabetic ketoacidosis (DKA) or patients have any risk factors for DKA
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 4
The effect of empagliflozin in patients with idiopathic edemaIdiopathic edema.Edema, unspecifiedR60.9IRCT20230314057712N1Ahvaz University of Medical Sciences70
Not yet recruiting
Phase 3
Assessment of effectiveness of Empagliflozin in the management of Anemia in diabetes patientsCTRI/2024/02/063292SRM Insitute of Science and Technology
Recruiting
Phase 3
Evaluation of the effectiveness of Empagliflozin on metabolic factors and liver function testsIRCT20191209045671N3Semnan University of Medical Sciences60
Not yet recruiting
Phase 3
Comparison of therapeutic effect of Empagliflozin (Gloripa) and Sitagliptin (Ziptin) on type 2 Diabetic patientsIRCT20200810048355N1Vice Chancellor for Research, Islamic Aazad University, Najafabad branch128
Recruiting
Phase 3
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90